...
首页> 外文期刊>European Journal of Case Reports in Internal Medicine >Delayed Use of the Recombinant Human IL-1 Receptor Antagonist Anakinra in Five COVID-19 Patients with Pulmonary Fibrosis and Persistent Hypoxaemia: A Preliminary Report
【24h】

Delayed Use of the Recombinant Human IL-1 Receptor Antagonist Anakinra in Five COVID-19 Patients with Pulmonary Fibrosis and Persistent Hypoxaemia: A Preliminary Report

机译:在五个Covid-19肺纤维化患者中延迟使用重组人IL-1受体拮抗剂Anakinra肺纤维化和持续低氧血症:初步报告

获取原文
           

摘要

Background:?Patients with sickle cell disease can experience various crises including sequestration crisis, haemolytic crisis and aplastic crisis. Due to alloantibody formation, transfusion alloantibodies can cause a haemolytic crisis. Treatment involves avoiding packed red blood cell transfusions, as well as intravenous immunoglobulin, steroids and eculizumab to decrease the chances of haemolysis. Case description:?We report the case of a 42-year-old man who was found to have worsening anaemia after packed red blood cell transfusion with evidence suggestive of haemolytic crisis. Due to reticulocytopenia, aplastic crisis was also suspected and later confirmed via parvovirus IgG and IgM titres. The patient did not improve with steroid and intravenous immunoglobulin therapy and was treated with eculizumab as a salvage therapy. Conclusion:?Concurrent hyper-haemolytic crisis and aplastic crisis should be suspected in patients with features of haemolysis and reticulocytopenia. Prompt recognition and treatment with eculizumab are paramount in those who fail steroid and intravenous immunoglobulin treatment.
机译:背景:患有镰状细胞疾病的患者可以体验各种危机,包括封存危机,血液解危机和制剂危机。由于Alloantibody形成,输血alloantibodies会导致溶血危机。治疗涉及避免包装的红细胞输血,以及静脉内免疫球蛋白,类固醇和肌肉,以降低溶血的可能性。案例描述:?我们举报了一个42岁男子的案例,其中被发现在填充红细胞输血后发现贫血患者的刺激性危及溶血危机。由于网状细胞间蛋白,也怀疑稳定危机,后来通过Parvovirus IgG和IgM滴度证实。患者没有用类固醇和静脉内免疫球蛋白疗法改善,并用Eculizumab作为救助治疗治疗。结论:α溶血和网状细胞缺乏症特征的患者应怀疑同时的超血液溶解危机和制剂危机。迅速识别和治疗生态珠宝是令人径向的,在这种失败类固醇和静脉内免疫球蛋白治疗的人中。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号